There are key genes that are recurrently mutated in various human cancers. Genomic DNA is isolated from bone marrow, aspirates, peripheral blood or formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the ABL1, ABL2, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, ATRX, AXL, B2M, BAP1, BCL2, BCL2L11, BCL6, BCOR, BIRC3, BRAF, BRCA1, BRCA2, BTK, CALR, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD33, CD79A, CD79B, CDH1, CDK2, CDK4, CDK6, CDKN1B, CDKN2A, CDKN2B, CEBPA, CHD1, CHEK2, CIC, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, CTNNB1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DIS3, DNMT3A, EBF1, EGFR, EGR1, EIF1AX, EP300, EPCAM, EPHA2, EPOR, ERBB2, ERBB3, ERBB4, ESR1, ETNK1, ETV6, EWSR1, EZH2, FAM46C, FAS, FAT1, FBXW7, FGF19, FGFR1, FGFR2, FGFR3, FLT1, FOXO1, FUBP1, GAB2, GATA2, GATA3, GNA11, GNA13, GNAI2, GNAQ, GNAS, GNB1, H3F3A, HIF1A, HIST1H1E, HNF1A, HRAS, ID3, IDH1, IDH2, IGF1R, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KLF2, KRAS, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K14, MAP3K9, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MET, MITF, MLH1, KMT2D, MPL, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NF1, NF2, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, PMS2, POLE, POT1, PPM1D, PRDM1, PRPS1, PTCH1, PTEN, PTPN11, RAC1, RAD21, RB1, REL, RET, RHEB, RHOA, RICTOR, RIPK1, RIT1, RNF43, ROS1, RPS15, RUNX1, S1PR2, SAMHD1, SETBP1, SETD2, SF3B1, SGK1, SH2B3, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SOCS1, SOX2, SPEN, SPOP, SRSF2, STAG2, STAT3, STAT5B, STAT6, STK11, TBL1XR1, TCF3, TERT, TET2, TGFBR1, TGFBR2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, TSC1, TSC2, U2AF1, UBR5, VHL, WT1, XPO1, ZFHX4, ZMYM3, and ZRSR2 genes is determined using next-generation sequencing (NGS) technology.
NexCourse® is a registered trademark of Genoptix, Inc.